Evidence map›Paper›PMID 37958300›Full record

ArticleCancers2023

Evaluating the Potential of Delta Radiomics for Assessing Tyrosine Kinase Inhibitor Treatment Response in Non-Small Cell Lung Cancer Patients.

Ting-Wei Wang, Heng-Sheng Chao, Hwa-Yen Chiu, Yi-Hui Lin, Hung-Chun Chen, Chia-Feng Lu, Chien-Yi Liao, Yen Lee, Tsu-Hui Shiao, Yuh-Min Chen and 2 more

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ting-Wei WangSchool of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.ORCID 0000-0001-7697-6024
Heng-Sheng ChaoDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan.ORCID 0000-0002-0309-0983
Hwa-Yen ChiuSchool of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.ORCID 0000-0001-8759-7871
Yi-Hui LinDepartment of Radiation Oncology, Taichung Veterans General Hospital, Taichung 407, Taiwan.
Hung-Chun ChenDepartment of Radiation Oncology, Taichung Veterans General Hospital, Taichung 407, Taiwan.
Chia-Feng LuDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Chien-Yi LiaoDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Yen LeeInstitute of Biophotonics, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Tsu-Hui ShiaoDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Yuh-Min ChenSchool of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.ORCID 0000-0003-0585-8463
Jing-Wen HuangDepartment of Radiation Oncology, Taichung Veterans General Hospital, Taichung 407, Taiwan.ORCID 0000-0003-2519-3227
Yu-Te WuInstitute of Biophotonics, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.ORCID 0000-0002-6942-0340

Funding

Gen. & Mrs. M.C. Peng Fellowship MD-SY-A3-309-01National Science and Technology Council in Taiwan MOST 110-2634-F-006- 022National Science and Technology Council in Taiwan MOST NSTC 111-2634-F-006-012.National Yang Ming Chiao Tung University from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, 111 W10159.Taichung Veterans General Hospital TCVGH-YMCT1109111
6 · The paper itself

Abstract

Our study aimed to harness the power of CT scans, observed over time, in predicting how lung adenocarcinoma patients might respond to a treatment known as EGFR-TKI. Analyzing scans from 322 advanced stage lung cancer patients, we identified distinct image-based patterns. By integrating these patterns with comprehensive clinical information, such as gene mutations and treatment regimens, our predictive capabilities were significantly enhanced. Interestingly, the precision of these predictions, particularly related to radiomics features, diminished when data from various centers were combined, suggesting that the approach requires standardization across facilities. This novel method offers a potential pathway to anticipate disease progression in lung adenocarcinoma patients treated with EGFR-TKI, laying the groundwork for more personalized treatments. To further validate this approach, extensive studies involving a larger cohort are pivotal.

Indexed as

computer tomography (CT) scansdelta radiomics signaturesepidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI)lung adenocarcinomapersonalized treatment strategiesprogression-free survival (PFS)time-variable radiomics

Identifiers

PMID37958300
PMCPMC10647242

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.